Vaccine events raising public concern and associated immunization program policy and practice changes, China, 2005-2021.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
20 04 2022
Historique:
received: 03 01 2022
revised: 12 03 2022
accepted: 14 03 2022
pubmed: 28 3 2022
medline: 13 4 2022
entrez: 27 3 2022
Statut: ppublish

Résumé

Several vaccine events causing public concern have occurred in China that were investigated and responded to by the central government. We describe causes, influences, and policy or practice changes associated with vaccine events that occurred between 2005 and 2021. We make recommendations to foster resilience in China's Expanded Program of Immunization (EPI) system and vaccination enterprises and to sustain vaccine and program confidence. Our study included all vaccine events since 2005 that were investigated and responded to by the central government of China. We verified mainstream and social media visibility of the events through Internet search. We extracted event times, causes, investigation processes, results, actions, and policy or practice regulation changes from official reports of government meetings and from official websites with media briefings. Seven vaccine events were identified, each of which caused more than 100,000 mainstream or social media reports nationally or nationally and internationally. The events ranged in magnitude from 145 children receiving out-of-date oral poliovirus vaccine to a measles supplementary immunization activity involving 103 million children. Few, if any, children were directly harmed by vaccines in the events. Government responded to each event with program or policy changes, and in one case, with legislation. Responses affected the conduct of campaigns and supplementary immunization activities, use of schools as vaccination venues, financial incentives for vaccinating with non-program vaccines, vaccine procurement and distribution, and program policy making. The most fundamental response was enacting the country's first vaccine law, the 2019 Vaccine Administration Law, which guides virtually all aspects of vaccination work, from vaccine development through regulation, program implementation, and safety and impact monitoring. All seven events generated substantial national and international mainstream and social media criticism and discussion, most commonly expressed through concerns of vaccine safety or vaccine effectiveness. Most had temporally associated temporary declines in vaccine confidence and coverage, jeopardizing decades of vaccination effort. The central government responded to each event by attempting to address root causes. Faithful implementation of the Vaccine Administration Law is fundamental to program strengthening and sustaining confidence of families, stakeholders, and government in vaccines and immunization in China.

Identifiants

pubmed: 35339307
pii: S0264-410X(22)00334-6
doi: 10.1016/j.vaccine.2022.03.035
pii:
doi:

Substances chimiques

Poliovirus Vaccine, Oral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2561-2567

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Xiaoxue Liu (X)

Jinan Center for Disease Control and Prevention, No.2 Weiliu Road, Huaiyin District, Jinan, Shandong 250021, China.

Wenzhou Yu (W)

Chinese Center for Disease Control and Prevention, No.27 Nanwei Road, Xicheng District, Beijing 100050, China. Electronic address: yuwz@chinacdc.cn.

Zundong Yin (Z)

Chinese Center for Disease Control and Prevention, No.27 Nanwei Road, Xicheng District, Beijing 100050, China.

Lance Rodewald (L)

Chinese Center for Disease Control and Prevention, No.27 Nanwei Road, Xicheng District, Beijing 100050, China.

Yifan Song (Y)

Chinese Center for Disease Control and Prevention, No.27 Nanwei Road, Xicheng District, Beijing 100050, China.

Zhaonan Zhang (Z)

Chinese Center for Disease Control and Prevention, No.27 Nanwei Road, Xicheng District, Beijing 100050, China.

Jiakai Ye (J)

Chinese Center for Disease Control and Prevention, No.27 Nanwei Road, Xicheng District, Beijing 100050, China.

Li Li (L)

Chinese Center for Disease Control and Prevention, No.27 Nanwei Road, Xicheng District, Beijing 100050, China.

Lei Cao (L)

Chinese Center for Disease Control and Prevention, No.27 Nanwei Road, Xicheng District, Beijing 100050, China.

Lingsheng Cao (L)

Chinese Center for Disease Control and Prevention, No.27 Nanwei Road, Xicheng District, Beijing 100050, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH